India’s leading healthcare focused venture & growth capital fund.
Included in the AvH investment portfolio since 2017
(Fund I) and 2020 (Fund II).
36.27 %
Beneficial interest AvH
Fund I
10.98 %
Beneficial interest AvH
Fund II
Press releases - Growth capital
View AllGrowth Capital
Biotalys Achieves Critical Manufacturing Milestone for First Commercial Biofungicide EVOCA® NG
Growth Capital
Biotalys’ First Commercial Biofungicide EVOCA® NG Approved for Large-Scale Commercial Field Trials in the Netherlands
Growth Capital